Eagle Pharmaceuticals Inc Working Capital to Net Assets Ratio
Eagle Pharmaceuticals Inc working capital to net assets ratio. Eagle Pharmaceuticals Inc (EGRX) has a Working Capital to Net Assets ratio of 39.9% as of June 2023. Working capital of $100.62 Million (current assets of $187.25 Million minus current liabilities of $86.63 Million) is measured against net assets of $252.04 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Eagle Pharmaceuticals Inc (2012–2022)
Working capital to net assets ratio of Eagle Pharmaceuticals Inc from 2012 to 2022. This chart shows how Eagle Pharmaceuticals Inc's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2012 to 2022. As of June 2023, the ratio stands at 39.9%, reflecting working capital of $100.62 Million against net assets of $252.04 Million USD. See EGRX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Eagle Pharmaceuticals Inc Working Capital to Net Assets Ratio by Year (2012–2022)
Eagle Pharmaceuticals Inc working capital to net assets ratio by year from 2012 to 2022. The table below presents the year-by-year Working Capital to Net Assets ratio for Eagle Pharmaceuticals Inc from 2012 to 2022, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see EGRX total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 33.3% | $77.67 Million | $233.56 Million | $188.75 Million | $111.09 Million | ▼ -22.4 pp |
| 2021 | 55.7% | $98.23 Million | $176.45 Million | $172.61 Million | $74.38 Million | ▼ -13.1 pp |
| 2020 | 68.8% | $127.98 Million | $186.01 Million | $166.06 Million | $38.09 Million | ▼ -9.7 pp |
| 2019 | 78.5% | $140.63 Million | $179.17 Million | $179.45 Million | $38.82 Million | ▲ +1.3 pp |
| 2018 | 77.2% | $124.16 Million | $160.76 Million | $163.84 Million | $39.69 Million | ▼ -1.7 pp |
| 2017 | 78.9% | $141.40 Million | $179.14 Million | $188.70 Million | $47.30 Million | ▲ +33.4 pp |
| 2016 | 45.6% | $68.89 Million | $151.23 Million | $109.11 Million | $40.22 Million | ▼ -51.8 pp |
| 2015 | 97.4% | $88.00 Million | $90.34 Million | $122.26 Million | $34.26 Million | ▼ -1.4 pp |
| 2014 | 98.8% | $32.71 Million | $33.10 Million | $53.02 Million | $20.32 Million | ▼ -54.1 pp |
| 2013 | 152.9% | $3.14 Million | $2.05 Million | $17.48 Million | $14.34 Million | ▲ +53.6 pp |
| 2012 | 99.3% | $-12.02 Million | $-12.10 Million | $8.86 Million | $20.88 Million | — |